Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models.
about
Tamoxifen Resistance: Emerging Molecular TargetsThe PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection.Association of Over-Expressed Estrogen Receptor Alpha with Development of Tamoxifen Resistant Hyperplasia and Adenocarcinomas in Genetically Engineered MiceThe Intestinal Microbiome and Estrogen Receptor-Positive Female Breast Cancer.
P2860
Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Assessing estrogen signaling a ...... cally engineered mouse models.
@ast
Assessing estrogen signaling a ...... cally engineered mouse models.
@en
type
label
Assessing estrogen signaling a ...... cally engineered mouse models.
@ast
Assessing estrogen signaling a ...... cally engineered mouse models.
@en
prefLabel
Assessing estrogen signaling a ...... cally engineered mouse models.
@ast
Assessing estrogen signaling a ...... cally engineered mouse models.
@en
P2093
P2860
P1476
Assessing estrogen signaling a ...... cally engineered mouse models.
@en
P2093
Edgar S Díaz-Cruz
M Carla Cabrera
Priscilla A Furth
Rebecca E Nakles
Sarah Millman
P2860
P304
P356
10.1111/J.1749-6632.2011.06086.X
P407
P577
2011-07-01T00:00:00Z